AnaptysBio Inc. (ANAB)’s Financial Results Comparing With Intellia Therapeutics Inc. (NASDAQ:NTLA)

Both AnaptysBio Inc. (NASDAQ:ANAB) and Intellia Therapeutics Inc. (NASDAQ:NTLA) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AnaptysBio Inc. 8.00M 222.37 51.52M -1.83 0.00
Intellia Therapeutics Inc. 29.22M 20.13 90.24M -2.16 0.00

Table 1 shows the gross revenue, earnings per share and valuation for AnaptysBio Inc. and Intellia Therapeutics Inc.


Table 2 demonstrates the net margins, return on assets and return on equity of AnaptysBio Inc. and Intellia Therapeutics Inc.

Net Margins Return on Equity Return on Assets
AnaptysBio Inc. -644.00% -14.9% -14%
Intellia Therapeutics Inc. -308.83% -31.7% -25.8%


AnaptysBio Inc. has a Current Ratio of 24.1 and a Quick Ratio of 24.1. Competitively, Intellia Therapeutics Inc.’s Current Ratio is 11.5 and has 11.5 Quick Ratio. AnaptysBio Inc.’s better ability to pay short and long-term obligations than Intellia Therapeutics Inc.

Insider and Institutional Ownership

AnaptysBio Inc. and Intellia Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 68.4%. Insiders owned roughly 0.7% of AnaptysBio Inc.’s shares. On the other hand, insiders owned about 28.44% of Intellia Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AnaptysBio Inc. -5.05% -17.9% -18.61% 0.71% -20.28% -29.7%
Intellia Therapeutics Inc. -7.82% -14.85% -38.81% -32.78% -21.9% -14.1%

For the past year AnaptysBio Inc. was more bearish than Intellia Therapeutics Inc.


On 6 of the 10 factors AnaptysBio Inc. beats Intellia Therapeutics Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.